Ehlers-Danlos Syndromes: Hypermobile, Vascular, and Classical Subtypes
2017 international classification, Beighton scoring for hEDS, vascular EDS arterial rupture risk, and multidisciplinary lifelong management.
Executive Summary
S1. Genetic Basis and 2017 International Classification
Collagen Biosynthesis Defects
Most EDS subtypes result from defects in collagen biosynthesis or modification. Collagen — the most abundant protein in the body — is assembled from procollagen polypeptide chains that fold into triple helices, undergo post-translational processing (hydroxylation of proline and lysine, glycosylation, cleavage of N- and C-propeptides), and self-assemble into fibrils crosslinked by lysyl oxidase. Mutations in genes encoding fibrillar collagens (Type I, III, V), processing enzymes (lysyl hydroxylase, procollagen N-proteinase), tenascin-X (matrix glycoprotein), and other matrix components produce the spectrum of EDS phenotypes. The clinical heterogeneity reflects which collagen type or processing step is disrupted and where that collagen is most abundant — Type I in skin/bone, Type III in vascular and hollow organs, Type V regulating Type I fibril diameter.
2017 International Classification: 13 Subtypes
| Subtype (2017) | Old name (1997) | Gene | Inheritance | Frequency |
|---|---|---|---|---|
| Classical EDS (cEDS) | EDS I, II | COL5A1, COL5A2 (rare COL1A1) | AD | ~1:20,000 |
| Classical-like EDS (clEDS) | — | TNXB | AR | Very rare |
| Cardiac-valvular EDS (cvEDS) | — | COL1A2 (biallelic) | AR | Very rare |
| Vascular EDS (vEDS) | EDS IV | COL3A1 (rare COL1A1) | AD | ~1:50,000–200,000 |
| Hypermobile EDS (hEDS) | EDS III | Unknown (clinical diagnosis) | AD | ~1:5,000 (most common) |
| Arthrochalasia EDS (aEDS) | EDS VIIA, B | COL1A1, COL1A2 | AD | Very rare |
| Dermatosparaxis EDS (dEDS) | EDS VIIC | ADAMTS2 | AR | Very rare |
| Kyphoscoliotic EDS (kEDS) | EDS VIA, B | PLOD1, FKBP14 | AR | Very rare |
| Brittle cornea syndrome (BCS) | — | ZNF469, PRDM5 | AR | Very rare |
| Spondylodysplastic EDS (spEDS) | — | B4GALT7, B3GALT6, SLC39A13 | AR | Very rare |
| Musculocontractural EDS (mcEDS) | — | CHST14, DSE | AR | Very rare |
| Myopathic EDS (mEDS) | — | COL12A1 | AD or AR | Very rare |
| Periodontal EDS (pEDS) | EDS VIII | C1R, C1S | AD | Very rare |
Mechanism Highlights
- Classical EDS: Heterozygous mutations in COL5A1 or COL5A2 cause haploinsufficiency or dominant-negative effects on Type V collagen, which regulates Type I collagen fibrillogenesis. Result: irregular collagen fibrils with reduced tensile strength.
- Vascular EDS: Heterozygous mutations in COL3A1 (Type III procollagen) produce abnormal homotrimers. Type III collagen is highly expressed in arteries, intestines, and uterus — explaining the predilection for arterial rupture, sigmoid colon perforation, and uterine rupture.
- Kyphoscoliotic EDS: Biallelic PLOD1 mutations eliminate lysyl hydroxylase 1 activity, impairing collagen crosslinking. Patients have congenital kyphoscoliosis, severe muscular hypotonia, and ocular fragility.
- Hypermobile EDS: No causative gene identified despite extensive sequencing efforts. Likely heterogeneous, polygenic, or non-collagen pathogenesis. The EDS Society 2017 explicitly retains clinical diagnostic criteria pending molecular discovery.
Hypermobility Spectrum Disorders (HSD)
Patients with symptomatic joint hypermobility who do not meet 2017 hEDS criteria are classified under “hypermobility spectrum disorders” (HSD), a category created in 2017 to acknowledge a continuum from asymptomatic generalized joint hypermobility through localized HSD, peripheral HSD, generalized HSD, to historical HSD. Management of HSD parallels hEDS, but the distinction matters for prognosis, family counseling, and research.
S2. Clinical Features and Beighton Hypermobility Score
Beighton Hypermobility Score (9-point Scale)
The Beighton score is a 9-point physical examination tool measuring generalized joint hypermobility:
| Maneuver | Points | Threshold |
|---|---|---|
| Passive dorsiflexion of 5th MCP joint | 1 point each side (2 total) | ≥90° |
| Passive apposition of thumb to volar forearm | 1 point each side (2 total) | Thumb touches forearm |
| Hyperextension of elbow | 1 point each side (2 total) | ≥10° beyond neutral |
| Hyperextension of knee | 1 point each side (2 total) | ≥10° beyond neutral |
| Forward flexion of trunk with palms flat on floor | 1 point | Knees fully extended |
Generalized joint hypermobility (GJH) thresholds adjusted for age:
- Prepubertal children: Beighton ≥6/9
- Pubertal to age 50: Beighton ≥5/9
- Age >50 years: Beighton ≥4/9 (joints stiffen with age)
Patients with documented historical hypermobility but current Beighton below threshold can use the 5-point hypermobility questionnaire (5PQ) — answering “yes” to 2+ of 5 questions counts as historical GJH.
Skin Signs
- Hyperextensibility: measured by stretching skin at neutral site (volar forearm) — abnormal if >1.5 cm in adults
- Atrophic (“cigarette paper”) scarring: typical in classical EDS; thin, widened, hyperpigmented scars at typical injury sites (knees, elbows, forehead, chin)
- Velvety/doughy skin texture: common in hEDS; described as “feeling like velvet”
- Soft and translucent skin: visible vessels through skin in vEDS; described as “thin” or “translucent”
- Easy bruising: all subtypes; striking and frequently mistaken for non-accidental injury or coagulopathy
- Molluscoid pseudotumors: small hemosiderin/calcium deposits at pressure points (cEDS)
- Subcutaneous spheroids: mobile pea-sized nodules over forearms/shins (cEDS)
Musculoskeletal Manifestations
Beyond hypermobility itself: chronic widespread musculoskeletal pain (often disabling, may meet fibromyalgia criteria), recurrent joint subluxations and dislocations (shoulder, patella, fingers, jaw), early-onset osteoarthritis, soft tissue injuries (tendinopathy, meniscal tears), low bone density, scoliosis, kyphosis, pes planus, hallux valgus, and temporomandibular joint dysfunction. Patients often report a history of being “double-jointed” since childhood, falling frequently, “loose joints,” and difficulty with high-impact sports.
Cardiovascular Manifestations
| Manifestation | Subtypes most affected | Detail |
|---|---|---|
| Mitral valve prolapse | cEDS, hEDS, cvEDS | Common but usually mild; routine echo at diagnosis |
| Aortic root dilation | cEDS, hEDS (mild), vEDS (variable) | Annual echocardiogram for cEDS; modest dilation common, rarely progresses |
| Arterial aneurysm and rupture | vEDS | Medium-large arteries; spontaneous, often without preceding aneurysm; cause of death in 50–70% of vEDS |
| Cervical artery dissection | vEDS | Spontaneous; mimics other arteriopathies (FMD, Marfan) |
| POTS / orthostatic intolerance | hEDS | Up to 70% of hEDS; tachycardia >30 bpm with standing without hypotension |
| Mitral or tricuspid regurgitation | cvEDS | Severe valvular disease, often requires replacement |
Gastrointestinal Manifestations
GI symptoms are highly prevalent in hEDS: early satiety, bloating, gastroparesis, functional dyspepsia, irritable bowel syndrome (IBS), constipation, GERD, abdominal pain, and rectal/uterine prolapse. Severe gastroparesis may require gastrostomy or parenteral nutrition in extreme cases. Vascular EDS carries the unique risk of spontaneous hollow organ perforation — sigmoid colon perforation accounts for the majority, often presenting as acute abdomen without preceding diverticulitis or known risk factor.
Autonomic and Other Systemic Features
Autonomic dysfunction is highly prevalent in hEDS: postural orthostatic tachycardia syndrome (POTS), neurally mediated syncope, dysautonomia symptoms (heat intolerance, sweating abnormalities, gastrointestinal motility issues, fatigue, sleep disturbance). Other features: easy bruising, varicose veins (often early-onset), chronic fatigue, anxiety and depression, headaches/migraines, hernias (inguinal, umbilical, hiatal, ventral), pelvic floor dysfunction, urinary stress incontinence, and craniocervical instability in selected severe hEDS.
S3. 2017 Diagnostic Criteria for hEDS, cEDS, and vEDS
Hypermobile EDS (hEDS) — 2017 Criteria
All three criteria (A, B, C) MUST be present:
Criterion A: Generalized Joint Hypermobility
Beighton score ≥6 (prepubertal), ≥5 (pubertal–50), or ≥4 (>50 years). If Beighton is one point below the threshold, two or more “yes” answers on the 5-Point Questionnaire confirm historical GJH.
Criterion B: Two or more of the following features (a, b, c) must be present
- Feature A — Systemic manifestations of generalized connective tissue disorder (5 of 12 must be present):
- Unusually soft or velvety skin
- Mild skin hyperextensibility
- Unexplained striae distensae or rubrae
- Bilateral piezogenic papules of the heel
- Recurrent or multiple abdominal hernias
- Atrophic scarring at two or more sites without papyraceous scars
- Pelvic floor, rectal, and/or uterine prolapse without history of risk factors
- Dental crowding and high or narrow palate
- Arachnodactyly (Steinberg sign or Walker-Murdoch sign)
- Arm span-to-height ratio ≥1.05
- Mitral valve prolapse on echocardiogram
- Aortic root dilatation with z-score >+2
- Feature B — Positive family history with one or more first-degree relatives independently meeting current diagnostic criteria for hEDS
- Feature C — Musculoskeletal complications (1 of 3 must be present): musculoskeletal pain in 2+ limbs daily for ≥3 months OR chronic widespread pain ≥3 months OR recurrent joint dislocations or frank joint instability in absence of trauma
Criterion C: All of the following prerequisites must be met
- No unusual skin fragility (excludes other EDS subtypes)
- Exclusion of other heritable and acquired connective tissue disorders (autoimmune rheumatologic conditions)
- Exclusion of alternative diagnoses including hypotonic disorders and myopathies
Classical EDS (cEDS) — 2017 Major and Minor Criteria
Major criteria: (1) skin hyperextensibility AND atrophic scarring, (2) generalized joint hypermobility (Beighton ≥5). Minor criteria include easy bruising, soft doughy skin, skin fragility, molluscoid pseudotumors, subcutaneous spheroids, hernias, epicanthal folds, complications of joint hypermobility, family history. Clinical diagnosis requires Major 1 PLUS either Major 2 OR ≥3 minor criteria. Molecular confirmation by genetic testing (COL5A1, COL5A2) is required for definitive diagnosis.
Vascular EDS (vEDS) — 2017 Major and Minor Criteria
Major criteria: (1) family history of vEDS with documented causative variant, (2) arterial rupture at young age, (3) spontaneous sigmoid colon perforation in absence of known diverticular disease or other bowel pathology, (4) uterine rupture during third trimester in absence of previous C-section and/or severe peripartum perineum tear, (5) carotid-cavernous sinus fistula formation in absence of trauma. Minor criteria include bruising unrelated to trauma, thin/translucent skin with visible veins, characteristic facial features, spontaneous pneumothorax, acrogeria, talipes equinovarus, congenital hip dislocation, hypermobility of small joints, tendon and muscle rupture, keratoconus, gingival recession, early-onset varicose veins. Molecular confirmation by COL3A1 testing is required.
⚠ Genetic Testing Strategy
The 2017 criteria mandate molecular genetic confirmation for ALL EDS subtypes EXCEPT hEDS. Initial testing is by next-generation sequencing panel covering COL5A1, COL5A2, COL3A1, COL1A1, COL1A2, TNXB, ADAMTS2, PLOD1, FKBP14, and other EDS genes. If the panel is negative and clinical suspicion remains high, exome or genome sequencing may be considered. Variant classification follows ACMG criteria. Genetic counseling is essential before testing to discuss implications, family screening, and reproductive considerations.S4. Vascular EDS Emergency Considerations
Lifetime Risk and Mortality Pattern
Vascular EDS is the most life-threatening EDS subtype. Without treatment, the median life expectancy is approximately 50 years. Major events occur in roughly 25% of patients by age 20 and over 80% by age 40. The leading causes of death are arterial rupture (50–70%), gastrointestinal perforation (10–25%), and uterine rupture during pregnancy (rare but devastating). Arterial events most commonly involve the medium-sized arteries: thoracic and abdominal aorta, splanchnic vessels (splenic, hepatic, mesenteric), iliac and renal arteries, cervical arteries (vertebral, carotid).
Spontaneous Arterial Events
A unique and dangerous feature of vEDS is that arterial rupture often occurs WITHOUT a preceding aneurysm — vessel walls fail at sites of normal caliber. This limits the role of aneurysm screening for prevention. Patients may present with sudden chest, abdominal, flank, or neck pain, syncope, or hemorrhagic shock. Imaging during acute events shows: spontaneous arterial dissection (most common), aneurysm with or without rupture, vessel rupture with hematoma, arteriovenous fistula, and pseudoaneurysm. Surgery and endovascular intervention carry markedly elevated complication rates due to fragile vessel walls — sutures cut through tissue, and clamping causes vessel disruption.
Hollow Organ Perforation
Spontaneous sigmoid colon perforation is the second most common life-threatening event in vEDS. Patients present with acute abdomen often without preceding GI symptoms, divertulitis, or known risk factor. Surgical management is challenging due to fragile bowel — primary repair frequently fails, prompting consideration of diverting colostomy. Recurrence after repair is common; some centers advocate elective colectomy after first perforation.
Imaging Surveillance
| Modality | Frequency | Purpose |
|---|---|---|
| Echocardiogram | Baseline and every 1–2 years | Aortic root diameter, valvular function |
| Whole-body MR angiography | Baseline and every 18–24 months (varies by guideline) | Arterial surveillance, aneurysm/dissection detection |
| CT angiography | For acute symptoms or events | Acute event characterization (preferred over MRA in unstable patients) |
Note: arterial catheterization (diagnostic angiography, cardiac catheterization) is associated with vessel injury and should be avoided when non-invasive imaging suffices. If catheterization is unavoidable, use the smallest feasible catheter and an experienced operator at a vEDS-experienced center.
Celiprolol Pharmacotherapy (BBEST Trial)
Celiprolol — a beta-1 antagonist with beta-2 partial agonist activity — is the only proven pharmacotherapy for vEDS. The BBEST trial (Lancet 2010) randomized 53 vEDS patients to celiprolol versus placebo and was stopped early after a 64% reduction in arterial events (5 vs 14 events) over 5 years of follow-up. Standard dosing is celiprolol 100 mg PO BID, titrated to 200 mg PO BID over 6 months as tolerated Celiprolol 100 mg PO BID → 200 mg PO BID. Despite limited evidence, celiprolol is now standard of care recommended at diagnosis. Note: celiprolol is unavailable in the US; alternatives include carvedilol or metoprolol succinate based on extrapolated benefit, though evidence is less robust.
Emergency Wallet Card and Patient Education
vEDS Patient Emergency Communication
Every vEDS patient should carry an emergency wallet card or wear a medical alert bracelet identifying the diagnosis. The card should specify: (1) vascular EDS with COL3A1 mutation, (2) high risk of arterial rupture and hollow organ perforation, (3) extreme caution with arterial puncture, surgery, and endoscopy, (4) avoidance of nonsteroidal anti-inflammatory drugs, anticoagulants when possible, (5) primary EDS specialist contact information. Patients should know to seek emergency care for any unexplained chest, abdominal, flank, or neck pain, sudden focal weakness, or syncope.★ Clinical Pearl
The classic vEDS presentation is a young (often 20–40 year old) patient presenting with sudden, severe abdominal pain due to spontaneous mesenteric or splenic artery rupture, OR sudden chest pain from spontaneous coronary artery or aortic dissection. Family history may reveal “early heart attack” or “sudden death” in young first-degree relatives — always pursue genetic counseling for unexplained vascular events in young adults.⚠ Pitfall
Reflexively performing arterial catheter intervention (catheter-directed thrombolysis, embolization, stent grafting) for vEDS patients without considering the markedly elevated procedural risk. Endovascular complications including catheter-related vessel injury and access site rupture are significantly more common than in non-EDS patients. Refer to a vEDS-experienced vascular surgeon when feasible.S5. Multidisciplinary Management and Pharmacotherapy
Physical Therapy and Joint Stabilization
Physiotherapy is the cornerstone of hEDS and cEDS management. Goals include: strengthening periarticular muscles to compensate for ligamentous laxity, improving joint proprioception, optimizing posture and biomechanics, and reducing pain. Programs emphasize low-impact exercises (swimming, stationary cycling, Pilates, yoga adapted for hypermobility), avoiding hyperextension, and progressive resistance with proper form. High-impact sports (running, contact sports, gymnastics, martial arts) should be limited or avoided. Bracing and orthoses (ankle braces, knee braces, ring splints for finger hyperextension) may help during activity.
Pain Management
Chronic pain affects most adults with hEDS and significantly impairs quality of life. Multimodal approach includes: (1) physical therapy and exercise (most effective long-term), (2) acetaminophen as first-line analgesic, (3) NSAIDs with caution (vascular EDS contraindication; GI considerations in others), (4) tricyclic antidepressants (amitriptyline 10–50 mg HS) for neuropathic and central sensitization pain, (5) duloxetine (60 mg/day) or gabapentinoids for neuropathic pain, (6) topical analgesics, (7) cognitive behavioral therapy for pain coping, (8) avoidance of long-term opioids. Referral to multidisciplinary pain medicine clinic is appropriate for refractory pain.
Autonomic Dysfunction Management
POTS and dysautonomia in hEDS are managed with: increased fluid (2.5–3 L/day) and salt (8–10 g/day if no contraindication) intake, compression garments (waist-high 20–30 mmHg), graduated upright tolerance, exercise reconditioning especially recumbent (recumbent bike, swimming), and pharmacotherapy when conservative measures fail. First-line POTS medications include: midodrine 2.5–10 mg PO TID Midodrine 2.5–10 mg PO TID, fludrocortisone 0.1–0.2 mg PO daily, beta-blockers (propranolol 10–20 mg PO QID for hyperadrenergic POTS), pyridostigmine 30–60 mg PO TID, and ivabradine 2.5–7.5 mg PO BID for inappropriate sinus tachycardia.
Cardiovascular Surveillance
| Subtype | Baseline | Surveillance |
|---|---|---|
| hEDS | Echocardiogram at diagnosis | Repeat every 5–10 years if normal; sooner if abnormal or symptomatic |
| cEDS | Echocardiogram at diagnosis | Repeat every 1–3 years (more frequent than hEDS due to aortic root risk) |
| vEDS | Echo + whole-body MRA + CTA aorta | Echo every 1–2 years; MRA every 18–24 months; vEDS-specialty cardiology |
| cvEDS | Echo + cardiology referral | Frequent surveillance; many require valve replacement |
Gastroenterology Care
For functional GI symptoms in hEDS: dietary modification (low FODMAP trial, small frequent meals), prokinetics for gastroparesis (metoclopramide 5–10 mg PO TID with FDA boxed warning awareness; erythromycin 50 mg PO TID alternative), antispasmodics for IBS (dicyclomine, hyoscyamine), constipation management (osmotic laxatives, polyethylene glycol). Endoscopy in vEDS carries risk and should be performed only when essential by experienced endoscopists with conscious sedation rather than deep sedation/general anesthesia when feasible.
Genetic Counseling
All EDS patients should receive genetic counseling at diagnosis covering: inheritance pattern (autosomal dominant for most EDS subtypes — 50% recurrence risk per pregnancy; autosomal recessive for kEDS, dEDS, mcEDS), family screening recommendations (first-degree relatives of probands with cEDS/vEDS should consider testing), reproductive options (prenatal diagnosis, preimplantation genetic diagnosis, donor gametes), implications for life and disability insurance.
S6. Pregnancy, Surgery, and Special Populations
Pregnancy in EDS
| Subtype | Pregnancy considerations |
|---|---|
| hEDS | Generally safe; increased risk of preterm labor (PROM), precipitous delivery, postpartum hemorrhage, perineal lacerations, and pelvic instability |
| cEDS | Increased risk of premature rupture of membranes, perineal lacerations, postpartum hemorrhage, uterine prolapse |
| vEDS | HIGH-RISK PREGNANCY — uterine rupture, arterial dissection (peripartum), maternal mortality 5–12% per pregnancy in older series. Cesarean delivery commonly recommended at 36 weeks. Manage at tertiary center with maternal-fetal medicine, vEDS-experienced obstetrics, vascular surgery, and anesthesia teams. |
| kEDS, dEDS | Pre-pregnancy genetic counseling for autosomal recessive transmission risk |
Surgical Considerations
All EDS patients undergoing surgery should have explicit communication of diagnosis and subtype to the surgical, anesthesia, and nursing teams in advance. Considerations include:
- Skin closure: deep, layered closure with non-absorbable suture; avoid removable staples in cEDS; leave sutures in 2× longer than usual; surgical glue may help
- Tissue handling: minimize traction on tissues; use atraumatic instruments
- Hemostasis: meticulous due to easy bruising and prolonged bleeding
- Anesthesia: regional anesthesia controversy in vEDS due to vessel puncture risk; assess case-by-case. Difficult intubation possible from cervical instability or TMJ hypermobility
- Vascular access: small-gauge catheters; ultrasound guidance; minimize venipuncture attempts
- Position: careful positioning to avoid joint subluxation/dislocation under anesthesia
- Hernia repair: high recurrence rate; mesh repair may be considered
Pediatric Presentation and Long-term Follow-up
Many patients present in childhood with delayed motor milestones, frequent falls, “loose joints,” easy bruising, and fatigue. Pediatric clinical features include: congenital hip dislocation (some forms), scoliosis (kEDS, others), inguinal hernias, recurrent joint sprains, growing pains, urinary incontinence beyond expected age, learning differences. Pediatric assessment is challenging because Beighton thresholds are higher (≥6/9) and many features evolve with age. Multidisciplinary pediatric EDS clinics are emerging at tertiary centers.
Mental Health and Quality of Life
Anxiety, depression, and chronic illness adjustment are highly prevalent across EDS subtypes (40–60% of adult patients). Multiple factors contribute: chronic pain, fatigue, autonomic symptoms, diagnostic delays (mean 10–15 years from symptom onset to diagnosis in hEDS), invalidating medical encounters, social isolation, and uncertainty about prognosis. Integration of mental health care (psychotherapy, antidepressants when indicated), patient support communities (Ehlers-Danlos Society and national affiliates), and validation are essential components of comprehensive care.
Avoidance Recommendations
Activities to Limit or Avoid (subtype-dependent)
- High-impact sports (running on hard surfaces, contact sports, gymnastics, martial arts, weightlifting with heavy loads) — joint injury risk in hEDS/cEDS
- Hyperextension stretches, “party tricks” demonstrating hypermobility — accelerated joint damage
- Smoking — accelerates connective tissue degradation; vasoconstriction in vEDS
- Anabolic steroids and stimulants without indication — vascular complications
- NSAIDs in vEDS (vascular bleeding risk); use cautiously in other subtypes
- Anticoagulation when possible in vEDS (bleeding/aneurysm rupture risk) — case-by-case for clear indications
- Air travel with unrepaired vEDS aortic disease — case-by-case
- Pregnancy in vEDS without explicit pre-conception counseling and high-risk obstetric care
FAQ
Practice Insights: Genetic Testing for vEDS Is Lifesaving, Celiprolol Reduces Arterial Events, Surgical Considerations Are Unique, Pregnancy in vEDS Requires Specific Counseling
Genetic Testing for vEDS — Must Confirm to Save Lives
In experienced practice every patient with features suggesting vEDS gets COL3A1 genetic testing. Why vEDS specifically: vEDS has the worst prognosis of EDS subtypes — vascular fragility produces arterial dissection/rupture (carotid, splenic, mesenteric, renal arteries; less commonly aortic), intestinal rupture (sigmoid most common), uterine rupture in pregnancy; median age at first major complication is in the 20s-30s; median life expectancy historically ~48 years without diagnosis, improving substantially with recognition and management. Clinical features suggesting vEDS: thin translucent skin with visible veins on chest and abdomen; characteristic facial features (small chin, thin lips, prominent eyes, lobeless ears); easy bruising disproportionate to trauma; family history of premature arterial events, intestinal rupture, or unexplained sudden death in <40 year-old relative; spontaneous pneumothorax; uterine rupture in pregnancy. Genetic testing: COL3A1 sequencing identifies pathogenic variants in >95% of clinical vEDS; cascade testing of all first-degree relatives once index case identified. What experienced practice does: low threshold to test in any patient with suspicious features; coordinate with genetic counseling; if positive, family cascade testing is essential. What experienced practice avoids: deferring genetic testing until “more features develop”; failing to test first-degree relatives after index case (sister, brother, parent, child each have 50% probability if dominant inheritance).
Celiprolol for vEDS — Reduces Arterial Events
Experienced practice would argue celiprolol is the standard pharmacotherapy for vEDS. Evidence base (BBEST trial, Ong et al. 2010): prospective open-label randomized trial in confirmed vEDS patients comparing celiprolol vs no treatment; demonstrated substantial reduction in arterial events (HR ~0.36) over median 5-year follow-up. Mechanism hypothesis: celiprolol is a β1-selective antagonist with β2-agonist properties; may reduce vascular wall stress and stabilize collagen; specific advantage over other beta-blockers unclear but evidence is for celiprolol. Standard dosing: starting 100 mg PO BID, titrated up to 400 mg/day in divided doses based on tolerance and heart rate response. Practice considerations: celiprolol availability is limited in some countries (FDA-approved in some markets, not others); alternative beta-blockers (carvedilol, metoprolol) may be considered but lack specific evidence in vEDS — use celiprolol when available. Adjunctive measures: blood pressure management (target SBP <130); avoid contact sports and isometric exercises; medical alert bracelet stating vEDS; emergency action plan for sudden severe pain (high suspicion for arterial dissection). What experienced practice does: initiate celiprolol at diagnosis; explain mechanism and rationale; monitor heart rate and tolerance; periodic vascular imaging (annual CT angiogram or MR angiogram of chest/abdomen/pelvis to detect aneurysms before rupture). What experienced practice avoids: deferring celiprolol “until more events occur”; aggressive blood pressure lowering with multiple agents (vasodilators may worsen aneurysm dynamics).
Surgical Considerations Are Unique Across All EDS
in experienced hands EDS surgical considerations are widely underappreciated. Preoperative planning: alert surgical team in advance about EDS diagnosis; provide them educational resources; identify if vEDS specifically (highest risk); plan for prolonged operative time; arrange ICU bed for vEDS or complex cases. Intraoperative considerations: minimize tissue handling; meticulous hemostasis (vessels tear easily and bleed extensively); reinforce sutures, avoid tension; use largest needles and finest non-absorbable suture material; consider mesh reinforcement for hernias; avoid harsh retractors; vEDS may require avoidance of arterial puncture and central lines if alternative access possible. Wound healing: 2-3× longer healing time than non-EDS patients; sutures left in place 2-3× longer (typically 14-21 days for cosmetic, 21-28 days for tension-bearing areas); steri-strips or surgical tape on wound for additional support during healing. Specific risks: dehiscence (failure of wound closure) common; herniation common at suture sites and incisions; vEDS specifically — postoperative arterial pseudoaneurysm at vascular access sites; intestinal anastomosis risks if abdominal surgery. Elective procedure decisions: weigh risk vs benefit carefully; cosmetic procedures generally discouraged; necessary procedures proceed with awareness; coordinate with patient about realistic expectations. What experienced practice avoids: assuming standard surgical care will produce normal outcomes; minimizing the impact of EDS during surgical planning; failing to anticipate prolonged recovery and complication risk.
Pregnancy in vEDS — Specific Counseling Required
Experienced practice would say pregnancy in vEDS deserves explicit pre-conception counseling. Maternal mortality risk: historical reports estimated 5-12% per pregnancy in vEDS, primarily from uterine rupture, arterial dissection, postpartum hemorrhage; modern care with MFM and cardiothoracic backup may reduce this but it remains substantial. Risks during pregnancy: arterial dissection (increased blood volume + vascular fragility); uterine rupture (rare in classic vEDS, but described, particularly in third trimester or with prior cesarean); preterm labor and PROM; postpartum hemorrhage; perineal lacerations difficult to repair. Pre-conception counseling experienced clinicians provide: explicit discussion of maternal mortality risk with available data; alternatives (surrogacy, gestational carrier — patient’s eggs in non-affected uterus); contraception options if pregnancy declined (sterilization considerations); cascade testing of partner if patient’s children’s risk needs assessment. If pregnancy pursued: MFM care from pre-conception; high-risk obstetric center delivery; CV imaging in first trimester baseline + as indicated; arterial catheter for blood pressure monitoring in labor avoided if possible; epidural anesthesia generally OK; planned cesarean for delivery (debated but commonly recommended given trauma risk and uterine fragility); intensive monitoring postpartum first 6 weeks. What experienced practice does: refer to MFM and genetics before conception; provide written materials; honor patient autonomy in reproductive decisions. What experienced practice avoids: dismissive counseling that minimizes risk; assuming patient knows the risks without explicit discussion; failing to coordinate cardiothoracic surgery backup if pregnancy proceeds.
Case: 25대 Female with Family History of Sister’s Sudden Death — vEDS Confirmed, Pregnancy Counseling Changed Plans
A woman in her mid-20s presented to genetics clinic. Family history significant: sister died at age 32 of “spontaneous arterial dissection” attributed to “weak blood vessels” but no genetic workup; maternal cousin died at age 28 in childbirth of “hemorrhage”; patient’s own features — translucent skin with visible veins on chest, easy bruising, mild joint hypermobility (Beighton 5), characteristic thin lips and prominent eyes. Genetic testing: COL3A1 sequencing — pathogenic missense mutation identified; vEDS confirmed. Family cascade testing initiated: father tested positive (silent carrier with mild features); mother negative; brothers and other relatives offered testing. Patient’s clinical management: celiprolol 100 mg BID started, titrated to 200 mg BID over 4 weeks (target HR 60-70); baseline CT angiogram chest/abdomen/pelvis — small aneurysmal dilation of splenic artery (7 mm), no critical findings; emergency action plan provided; medical alert bracelet ordered; avoid contact sports/heavy lifting/isometric exercise. Pregnancy counseling: patient and her partner were planning pregnancy; explicit discussion of ~5-12% maternal mortality risk per pregnancy historically (better with modern care but not zero); offered alternatives including surrogacy with patient’s eggs in non-affected gestational carrier. After 6 months of consideration, patient and partner chose surrogacy via gestational carrier; IVF performed, surrogate completed successful pregnancy delivering healthy infant; infant tested in newborn period: positive for COL3A1 mutation (50% transmission risk). 2-year follow-up: patient stable on celiprolol; splenic artery aneurysm unchanged on annual imaging; no arterial events; child managed by pediatric vEDS clinic; family members appropriately counseled and managed.
Protocol Tweaks Seasoned Clinicians Apply (Practice Refinements)
- Low threshold for COL3A1 genetic testing in suspicious cases: thin translucent skin, characteristic facies, family history of premature arterial events, spontaneous pneumothorax. Cascade test relatives once index identified.
- Celiprolol 100-400 mg/day in confirmed vEDS: BBEST trial evidence; titrate to HR 60-70; alternative beta-blocker if celiprolol unavailable. Annual CT/MR angiogram surveillance.
- Surgical alerts and modifications across all EDS: surgeon notification, meticulous hemostasis, sutures retained 2-3× longer, mesh reinforcement, ICU consideration for major surgery in vEDS.
- Pregnancy counseling pre-conception: explicit maternal mortality data; offer alternatives (surrogacy, gestational carrier); MFM care if pregnancy pursued; planned cesarean commonly recommended in vEDS.
- Gout: ACR 2020 Management, Urate-Lowering Therapy, and Flare Control
- Systemic Sclerosis (Scleroderma): Classification, Organ Involvement, and Disease-Modifying Therapy
- Reactive Arthritis: Diagnosis, Pathogenesis, and Management
- Calcium Pyrophosphate Deposition Disease (Pseudogout): Diagnosis and Management
- Sarcoid Arthropathy: Löfgren Syndrome, Chronic Sarcoid Arthritis, Imaging, and Treatment
- Hypermobility Spectrum Disorder and hEDS: Diagnosis and Management